<DOC>
	<DOCNO>NCT01985295</DOCNO>
	<brief_summary>In study , aim define recommend dose VEGFR-TKI ( pazopanib ) combination RT pre-operatively give .</brief_summary>
	<brief_title>Combined Modality Treatment Sarcomas Extremities</brief_title>
	<detailed_description>Study design A dose escalation trial Pazopanib , start 400mg daily , orally combination standard 25 x 2Gy preoperative radiotherapy newly diagnose extremity sarcoma patient . Dose pazopanib escalate via 600mg maximally 800mg . Overall treatment time pazopanib 40 day . Treatment plan : Pazopanib Dose level Dose pazopanib orally , daily , # patient 1 . ( start ) 400 mg 3 2 . 600 mg 3 3 . ( maximum ) 800 mg 3 Treatment plan : radiotherapy RT give 5 week daily fraction 2 Gray ( 50 Gray 25 daily fraction ) RT planning : The dose planning perform CT base Intensity Modulated RT ( IMRT ) 3 Dimensional Conformal RT ( 3D-RT ) accord local planning protocol participate institute . Dose specification : According ICRU 50/62 .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>1 . Histologically confirm newly diagnose intermediate high grade soft tissue sarcoma localize extremity head neck area treatment combination surgery radiotherapy ( deep seat , &gt; 5cm accord RECIST 1.1 criterion , grade II/III accord WHO definition ) . 2 . Age &gt; 18 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 4 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 5 . Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . 6 Able swallow retain oral medication . 7 . A life expectancy least 12 week . 8 . Adequate organ function . 1 . Prior malignancy ; except subject another malignancy diseasefree 5 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . 2 . Patients recurrent sarcoma ( even without prior radiotherapy ) . 3 . Ewing sarcoma PNET family tumour , rhabdomyosarcoma ( pediatric adult ) , osteosarcoma . 4 . Clinically significant gastrointestinal abnormality might interfere oral dose diagnose : Active peptic ulcer disease . Known intraluminal metastatic lesion suspect bleed . Inflammatory bowel disease , ulcerative colitis , gastrointestinal condition increase risk perforation . History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . Major resection stomach small bowel . 5 . Uncontrolled hypertension . 6 . Unstable serious concurrent condition ( e.g. , active infection require systemic therapy ) . 7 . Prolongation correct QT interval ( QTc ) &gt; 480 msec . 8 . History one follow cardiovascular condition within past 6 month : 1 . Cardiac angioplasty stenting . 2 . Myocardial infarction . 3 . Unstable angina . 4 . Symptomatic peripheral vascular disease . 5 . Coronary artery bypass graft surgery . 6 . Class II , III IV congestive heart failure define New York Heart Association ( NYHA ) . 7 . History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . 9 . Macroscopic hematuria 10 . Haemoptysis clinically relevant within 4 week first dose study drug . 11 . Evidence active bleeding bleed diathesis . 12 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . 13 . Chemotherapy radiation therapy within 2 week prior first dose study drug . 14 . Biological therapy treatment investigational agent within 28 day 5 halflives , whichever long prior first dose study drug . 15 . Prohibited medication list protocol 14 day five halflives drug ( whichever longer ) prior Visit 1 duration study take . 16 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib . 17 . Pregnancy lactate . 18 . Hypothyroidism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>